{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104092","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.261101+00:00","generated_at":"2026-05-17T18:51:08.275511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia Q2 revenue $264.6M (+9% YoY); NUPLAZID guidance raised to $665-690M","bullets":["Total revenue $264.6M, NUPLAZID $168.5M (+7%), DAYBUE $96.1M (+14%).","Net income $26.7M ($0.16 EPS) vs $33.4M ($0.20 EPS) YoY due to higher tax rate.","Raised NUPLAZID net sales guidance low end to $665M; total revenue guidance $1.045-1.095B.","Patent litigation wins affirm NUPLAZID exclusivity through 2030 (composition) and 2038 (formulation).","COMPASS PWS Phase 3 study enrollment complete; top-line results expected early Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104092","json":"https://secwatch.observer/filing/0000950170-25-104092.json","markdown":"https://secwatch.observer/filing/0000950170-25-104092.md","text":"https://secwatch.observer/filing/0000950170-25-104092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017025104092/0000950170-25-104092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017025104092/acad-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:51:08.275511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}